SLS
Income statement / Annual
Last year (2023), SELLAS Life Sciences Group, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2023, SELLAS Life Sciences Group, Inc.'s net income was -$37.34 M.
See SELLAS Life Sciences Group, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$1.00 M
|
$7.60 M
|
$1.90 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$9.32 M
|
| Cost of Revenue |
$0.00 |
$100,000.00 |
$200,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$3,000.00 |
$355,000.00 |
$1.40 M |
| Gross Profit |
$0.00 |
$900,000.00 |
$7.40 M |
$1.90 M |
$0.00 |
$0.00 |
$0.00 |
-$3,000.00 |
-$355,000.00 |
$7.92 M |
| Gross Profit Ratio |
0 |
0.9 |
0.97 |
1 |
0 |
0 |
0 |
0 |
0 |
0.85 |
| Research and Development
Expenses |
$24.01 M
|
$30.27 M
|
$21.37 M
|
$9.28 M
|
$7.29 M
|
$18.32 M
|
$6.07 M
|
$19.86 M
|
$23.61 M
|
$28.35 M
|
| General & Administrative
Expenses |
$13.86 M
|
$12.58 M
|
$11.32 M
|
$9.60 M
|
$9.92 M
|
$12.77 M
|
$15.09 M
|
$12.01 M
|
$10.61 M
|
$31.34 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$13.86 M
|
$12.58 M
|
$11.32 M
|
$9.60 M
|
$9.92 M
|
$12.77 M
|
$15.09 M
|
$12.01 M
|
$10.61 M
|
$31.34 M
|
| Other Expenses |
$0.00 |
$10.00 M |
$5.70 M |
$0.00 |
$0.00 |
-$3.03 M |
$0.00 |
$0.00 |
$509,000.00 |
$170,000.00 |
| Operating Expenses |
$37.87 M |
$42.85 M |
$32.69 M |
$18.88 M |
$17.21 M |
$31.09 M |
$21.16 M |
$31.87 M |
$34.22 M |
$60.14 M |
| Cost And Expenses |
$37.87 M |
$42.95 M |
$32.89 M |
$18.88 M |
$17.21 M |
$31.09 M |
$21.16 M |
$31.87 M |
$34.22 M |
$61.54 M |
| Interest Income |
$525,000.00 |
$317,000.00 |
$6,000.00 |
$26,000.00 |
$118,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$118,000.00 |
$266,000.00 |
$462,000.00 |
$3.51 M |
$760,000.00 |
$1.11 M |
| Depreciation &
Amortization |
$37.87 M
|
$457,000.00
|
$1.27 M
|
$377,000.00
|
$17.21 M
|
$22.04 M
|
$3,000.00
|
$3,000.00
|
$355,000.00
|
$440,000.00
|
| EBITDA |
$529,000.00
|
-$31.95 M
|
-$19.66 M
|
-$16.40 M
|
$668,000.00
|
$0.00
|
-$23.04 M
|
-$15.99 M
|
-$37.48 M
|
-$36.61 M
|
| EBITDA Ratio |
0 |
-42.28 |
-3.9 |
-8.89 |
0 |
0 |
0 |
0 |
0 |
-7.33 |
| Operating Income Ratio
|
0
|
-41.95
|
-3.33
|
-8.94
|
0
|
0
|
0
|
0
|
0
|
-5.6
|
| Total Other
Income/Expenses Net |
$529,000.00
|
$649,000.00
|
$4.36 M
|
$208,000.00
|
$668,000.00
|
$2.54 M
|
-$7.79 M
|
$5.13 M
|
-$4.37 M
|
$13.62 M
|
| Income Before Tax |
-$37.34 M |
-$41.30 M |
-$20.94 M |
-$16.77 M |
-$19.37 M |
-$29.05 M |
-$23.50 M |
-$10.86 M |
-$38.59 M |
-$36.61 M |
| Income Before Tax Ratio
|
0
|
-41.3
|
-2.75
|
-8.83
|
0
|
0
|
0
|
0
|
0
|
-3.93
|
| Income Tax Expense |
$0.00 |
-$649,000.00 |
-$237,000.00 |
-$17,000.00 |
-$81,000.00 |
-$1.38 M |
$253,000.00 |
$243,000.00 |
$365,000.00 |
-$15.45 M |
| Net Income |
-$37.34 M |
-$40.65 M |
-$20.70 M |
-$16.76 M |
-$19.29 M |
-$27.67 M |
-$23.75 M |
-$23.55 M |
-$63.90 M |
-$36.61 M |
| Net Income Ratio |
0 |
-40.65 |
-2.72 |
-8.82 |
0 |
0 |
0 |
0 |
0 |
-3.93 |
| EPS |
-1.34 |
-2.1 |
-1.34 |
-2.1 |
-7.54 |
-105.8 |
-507.49 |
-3547.07 |
-12348.28 |
-9199.8 |
| EPS Diluted |
-1.34 |
-2.1 |
-1.34 |
-2.1 |
-7.54 |
-105.8 |
-507.49 |
-3547.07 |
-12348.21 |
-9199.8 |
| Weighted Average Shares
Out |
$27.78 M
|
$19.40 M
|
$15.48 M
|
$7.98 M
|
$2.56 M
|
$261,542.00
|
$46,807.00
|
$6,639.00
|
$5,174.97
|
$3,979.00
|
| Weighted Average Shares
Out Diluted |
$27.78 M
|
$19.40 M
|
$15.48 M
|
$7.98 M
|
$2.56 M
|
$261,542.00
|
$46,807.00
|
$6,639.00
|
$5,175.00
|
$3,979.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
